Growth

In this article we examine some key themes in US equities, and how the last 3 months have created tailwinds for the Nasdaq 100.

One of Australia’s top small-cap PM's in FY25 began investing as a teen, with a Domino’s paycheck, and a hunch on Fortescue.

In the world of tech, identifying future market leaders can be akin to finding a needle in a haystack. But the rewards can be monumental.

Forager’s Steve Johnson has trimmed winners, raised cash and is eyeing beaten-up small caps as reporting season kicks off.

Hyperion, Antipodes and Plato share their biggest stock calls and global market outlooks at the recent Pinnacle Summit.

After nearly three decades at IML, Simon Conn reflects on investing through cycles, what matters most, and two stocks he still rates today.

16 seasons of data reveal stocks beating earnings forecasts gain 5.2% on results day and often continue trending higher for several months.

Elston’s Bruce Williams discuss ResMed's results and margin momentum, and whether the stock still deserves a buy rating.

After crashing more than 30% this week, Novo Nordisk has now seen its share price fall 65% over the last 12 months.

There’s more to ASX financials than the Big Four. Matt Williams (Airlie) and David Wilson (First Sentier) reveal where they're seeing value.